Physician profile
Deborah Pasik
NPI 1992894794
$1,368.31
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,029 · 2020: $324 · 2021: $14.99.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $292.72 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $265.68 | 2019-2020 | |
| Glaxosmithkline, LLC. | $208.17 | 2019-2020 | |
| Abbvie INC. | $181.48 | 2019-2020 | |
| Amgen INC. | $100.84 | 2019-2021 | |
| Pfizer INC. | $80.10 | 2019-2020 | |
| Genzyme Corporation | $58.13 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $43.36 | 2019-2020 | |
| Ucb, INC. | $40.37 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $27.89 | 2019-2020 | |
| Genentech USA, INC. | $27.29 | 2019-2020 | |
| Pacira Therapeutics, INC. | $27.28 | 2019-2020 | |
| Sobi, INC | $15.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Pasik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.